Novartis is investing $256 million to expand its biopharmaceutical manufacturing plant in Singapore, focusing on therapeutic antibody drugs for skin and respiratory diseases. The expansion will double the plant's output and create 100 high-skilled new jobs.
Swiss pharmaceutical giant Novartis is investing $256 million to expand its biopharmaceutical manufacturing plant in Singapore . The facility will focus on manufacturing therapeutic antibody drugs for skin and respiratory diseases . Digital and automation solutions will be implemented to improve productivity and operational efficiency . The plant currently produces 140 batches a year and the expansion will more than double that output.
Novartis will also provide training programs to upskill its workforce and create 100 high-skilled new jobs
Novartis Biopharmaceutical Manufacturing Plant Singapore Therapeutic Antibody Drugs Skin Diseases Respiratory Diseases Productivity Operational Efficiency Jobs